Prime Medicine, Inc.

Prime Medicine, Inc.

PRME·NASDAQ

$3.14

-2.2%
HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$567.14M
EPS-1.3500
P/E Ratio-2.33
Earnings Date08/06/2026

prme

Depreciation and Amortization

Last Annual Value

5.38M

3-Year CAGR

34%

5-Year CAGR

163%

10-Year CAGR

%

Prime Medicine, Inc.

Prime Medicine, Inc. Competitors Analysis of Depreciation and Amortization

PRME · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
5.38M
5.0%56.8%N/A 
PROK logo
ProKidney Corp.
NASDAQ:PROK
6.58M
19.5%27.1%N/A
-7.46M
N/AN/AN/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
1.60M
23.7%N/AN/A
2.31M
70.7%-3.6%9.8%
3.50M
12.7%15.4%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
31.00K
1.1%19.0%-27.3%
60.47M
7.4%19.6%N/A
546.00K
15.6%31.3%N/A
21.15M
2.8%29.5%N/A
406.00K
177.5%N/AN/A
Prime Medicine, Inc.

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

Intrinsic Value
Current Price: $3.14